ocket No. 55600-800

certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Ass Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Sokawa et al.

APPLICATION NO.:

09/910,406

FILED:

July 19, 2001

FOR: COMPOSITION FOR TREATMENT OF AND METHOD

OF MONITORING HEPATITIS C VIRUS USING

INTERFERON-TAU

EXAMINER: Wortman, Donna C.

ART UNIT:

CONF. NO:

1646 9683 RECEIVED TECT VENTER 1600/2900

Supplemental Information Disclosure Statement Within Three Months of Application Filing or Before First Action – 37 CFR 1.97(b)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 CFR 1.97(b)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

- \boxtimes Copies of the following references are enclosed:
 - All cited references \boxtimes
 - References marked by asterisks
 - The following: Copy of International Search Report for Int'l. Appln. No. \boxtimes PCT/US01/22976; filed July 19, 2001.

Copies of the following references can be found in parent U.S. Application No. :						
☐ All cited references☐ References marked by asterisks☐ The following:						
The following references are not in English. For each such reference undersigned has enclosed (i) a translation of the reference; (ii) a copy communication from a foreign patent office or International Searching Aut citing the reference, (iii) a copy of a reference which appears to be an En language counterpart, or (iv) an English-language abstract for the reference by a third party. Applicant has not verified that the translation, En language counterpart or third-party abstract is an accurate representation of teachings of the non-English reference, though, and reserves the rig demonstrate otherwise.						
☐ All cited references☐ References marked by ampersands☐ The following:						

3. Effect of Information Disclosure Statement (37 CFR 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due. However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 CFR 1.704(d))

The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted, Perkins Coie LLP


Date: 3-4-03

Larry W. Thrower

Registration No. 47,994

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300



		 			U	S. PATENT DOCUMENTS	······································		
Examiner Initials*	Cite	e	S. Patent or Ap	plication Kind Cod (if knowr		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Line Where Relevant Passage Relevant Figures Appe	es or
								D~	
					_			TECEU.	
	_							RECEIVED MAR 1 2 2003 CENTER 1600)
							TECH	2 2003	
	_	_	***		-			CENTED 16000	
 					_ _			1000/2900	
					FOF	REIGN PATENT DOCUMENTS			
Examiner Initials*	Cite No.	For Office	reign Patent or A	Kind		Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
			WO00/7	8266		Univ of Maryland College Park	12/28/2000		
			WO96/3	5789		The Women's Research Institute	11/14/1996		
			_						
					ļ <i>-</i>				
	<u></u>		OTHE) V D.	I T-NON PATENT LITERATURE D	OCUMENTS		<u> </u>
	<u> </u>					in CAPITAL LETTERS), title of the article), title of the item	
Examiner Initials*	xaminer Cite (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city							_T	
Clayette, P., et al., "IFN – tau, a new interferon type I with antiretroviral <i>Pathologie Biologiel, 47:4 553-559 (1999).</i>							oviral activity,"		
Saez-Royuela, F., et al., "Treatment of Chronic Non-A Non-B Hepatitis Doses of Recombinant IFN-ALPHA or Recobinant IFN-TAU," 40 th Annuthe American Association for the Study of Liver Diseases, Chicago, IL, 10:4 646 (1989).						Annual Meeting of			

EXAMINER	And the state of t	DATE CONSIDERED				
*EVANDED	7 10 1 10 C	war as with MDED 600. Draw line through sitution if not in conformance and not				
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).					